Organogenesis Holdings Inc.(ORGO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Organogenesis Holdings Inc. (ORGO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ORGO at 30.4/100 on a 32-signal composite quality model, placing it at rank #2,491 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (11.2) and profitability (14.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 37.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Organogenesis Holdings Inc. reports quarterly revenue of $43.8M, net income of $-96.3M, free cash flow of $-32.8M. Top institutional holders of ORGO by reported 13-F value include MORGAN STANLEY, Soleus Capital Management, L.P., BlackRock, based on the most recent SEC filings. ORGO trades on the Nasdaq exchange and files with the SEC under CIK 1661181. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ORGO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Organogenesis Holdings Inc. directly from SEC EDGAR.